Protalix BioTherapeutics Inc(PLX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 11.41 | EPS (ttm) | 0.23 | Insider Own | 9.04% | Shs Outstand | 80.6M | Perf Week | 0.78% |
| Market Cap | 0.21B | Forward P/E | 51.8 | EPS next Y | -79.17% | Insider Trans | - | Shs Float | 73.3M | Perf Month | -3.72% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.02 | Inst Own | 19.56% | Short Float | 4.79% | Perf Quarter | 14.1% |
| Income | 0.02B | P/S | 2.59 | EPS this Y | 400% | Inst Trans | 2.98% | Short Ratio | 4.42 | Perf Half Y | 22.17% |
| Sales | 0.08B | P/B | 2.92 | EPS next 5Y | - | ROA | 20.07% | Short Interest | 3.51M | Perf YTD | 43.89% |
| Book/sh | 0.89 | P/C | 5.04 | EPS past 3/5Y | 35.12% 17.78% | ROE | 31.23% | 52W High | -18.81% ($3.19) | Perf Year | 12.61% |
| Cash/sh | 0.51 | P/FCF | 27.21 | Sales past 3/5Y | 3.45% -3.46% | ROIC | 24% | 52W Low | 56.97% ($1.65) | Perf 3Y | 81.12% |
| Dividend Est. | - | EV/EBITDA | 7.1 | EPS Y/Y TTM | 181.54% | Gross Margin | 69.2% | Volatility(W/M) | 3.71% 3.98% | Perf 5Y | 131.25% |
| Dividend TTM | - | EV/Sales | 2.19 | Sales Y/Y TTM | 30.14% | Oper. Margin | 28.89% | ATR (14) | 0.1 | Perf 10Y | -47.14% |
| Dividend Ex-Date | - | Quick Ratio | 1.91 | EPS Q/Q | 2190% | Profit Margin | 23.5% | RSI (14) | 47.26 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.94 | Sales Q/Q | 27.07% | SMA20 | -2.21% ($2.65) | Beta | 0 | Target Price | $11 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/12 | SMA50 | -1.71% ($2.64) | Rel Volume | 0.74 | Prev Close | $2.53 |
| Employees | 226 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 600% 53.64% | SMA200 | 7.55% ($2.41) | Avg Volume(3M) | 0.79M | Price | $2.59 |
| IPO | 1996/4/9 | Option/Short | Yes/Yes | Trades | 1871 | Volume | 590,570 | Change | 2.37% |
🧬 An Israel-based commercial-stage biopharmaceutical company that develops and manufactures treatments for rare diseases using its proprietary plant cell-based expression platform, ProCellEx. Founded in 1993 and headquartered in Karmiel, Israel, the company is commercializing Elfabrio, a treatment for Fabry disease, in collaboration with a global partner.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
PLX makes money exceptionally well
Of every $100 in sales, $28.89 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +400.0% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $1,141. Peers typically go for $1,452. Compared with its own 3-year average, it is 17% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +131.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 19.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #296 of 594 in the industry
Based on market cap of $209M.
ARTV#295 Artiva Biotherapeutics Inc $209M PER - PLX#296 Protalix BioTherapeutics Inc $209M PER 11.4 
PALI#297 Palisade Bio Inc $207M PER - 
DTIL#298 Precision Biosciences Inc $206M PER - 
KRRO#299 Korro Bio Inc $204M PER - 
FAQ
What kind of company is PLX?
PLX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PLX?
The market cap of PLX is approximately $209M, ranking 3,993 within its sector.
What is the P/E ratio of PLX?
PLX has a P/E ratio of approximately 11.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PLX?
PLX has recorded a 52-week high of $3.19 and a low of $1.65.
